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Abstract
The term epigenetics is defined as heritable changes in gene expression that are not due to alterations of the DNA
sequence. In the last years, it has become more and more evident that dysregulated epigenetic regulatory processes
have a central role in cancer onset and progression. In contrast to DNA mutations, epigenetic modifications are
reversible and, hence, suitable for pharmacological interventions. Reversible histone methylation is an important
process within epigenetic regulation, and the investigation of its role in cancer has led to the identification of lysine
methyltransferases and demethylases as promising targets for new anticancer drugs. In this review, we describe those
enzymes and their inhibitors that have already reached the first stages of clinical trials in cancer therapy, namely the
histone methyltransferases DOT1L and EZH2 as well as the demethylase LSD1.
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Background
All cells within one individual contain the same genetic
information in the DNA; however, gene expression and
hence phenotypes vary widely in different cells and tis-
sues. In the nucleus, the DNA is packaged together with
structural proteins (histones) to form a complex known
as chromatin. Chromatin can appear in a condensed,
transcriptionally repressed form (heterochromatin) or in
a generally decondensed, and transcriptionally active
form (euchromatin). The local regulation of chromatin
state is believed to control accessibility to DNA, allow-
ing, respectively, control of transcription, replication, re-
combination, and DNA repair. Different epigenetic
mechanisms affect the chromatin state. These consist of
histone post-translational modifications (PTMs) [1, 2],
DNA modifications [3], replacement of canonical his-
tones with histone variants [4], ATP-dependent nucleo-
some remodeling [5, 6], non-coding RNA (ncRNAs) [7],
and others [8–10]. Here, we will focus on histone modi-
fications, specifically reversible histone methylation.
A nucleosome, the repeating unit of chromatin, is
composed of a histone octamer core, which consists of
two copies of each histone H2A, H2B, H3, and H4 pro-
teins, and a short segment of DNA, between 145 and
147 base pairs, which is wrapped around it (Fig. 1). The
repeating nucleosome cores further assemble into higher
order structures which are stabilized by the linker his-
tone H1 [11]. The core is predominantly globular except
for the histone tails (~30 amino acids) protruding from
them. A wide range of PTMs occurs not only at the
histone N-terminal tails, including acetylation, methyla-
tion, phosphorylation, ubiquitination, SUMOylation, cro-
tonylation, and others [12] but also in the core of the
histones and in the C-terminal regions [13, 14]. The en-
zymes responsible of the addition of chemical groups
onto either histone tails or the DNA itself are commonly
termed “writers”, the proteins that recognize these spe-
cific epigenetic marks are called “readers”, and then,
since the epigenetic modifications are not permanent,
the “erasers” can remove them. In histone tails, lysine
and arginine residues are the main sites of modifications
(principally acetylation and methylation). It is interesting
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to note that several histone lysines can be substrates of
methylation as well as of acetylation processes (Fig. 1). A
balance between these two competitive modifications at
H3K9 is, for example, required for chromosome segrega-
tion [15]. While the acetylation of the lysine directly
abolishes the positive charge of the amino acid, eliminat-
ing the electrostatic bond between histones and DNA,
thus allowing the euchromatin formation, histone lysine
and arginine methylation do not alter the charge [16].
These modifications influence instead the binding of
chromatin-associated proteins; different readers that
specifically recognize these modifications have been de-
scribed [17].
The enzymatic methylation of histones is performed
by lysine methyltransferases (KMTs) and arginine
methyltransferases (PRMTs), with S-adenosyl-L-me-
thionine (SAM) as the methyl donor. Histone methy-
lation can involve the transfer of up to three methyl
groups, thus resulting in mono-, di-, or trimethylated
lysine, respectively, and in mono- or di- (asymmetric
or symmetric) methylated arginine. Surprisingly, the
same modifications could also lead to opposite activ-
ities (e.g., H3K4me2 and H3K4me3) probably due to
the recruitment of different effector proteins by the
readers [18, 19]. Hence, the discussion around the
existence of a histone code [20] has lately shifted to
calling it rather a language which emphasizes the
context dependence of the modifications [2].
The demethylation of lysines was for a long time
thought to be irreversible, until Shi et al. reported in 2004
that the amine oxidase lysine-specific demethylase 1A
(LSD1; also known as KDM1A) was able to specific-
ally demethylate histone H3 lysine 4 (H3K4) [21]. For
arginines, the existence of a “true” demethylase
remains to be proven [22]. Arginine as well as mono-
methylated arginine can, however, be converted to
citrulline by the protein-arginine deiminases (called
PADs or PADIs) [23].
The most extensively studied histone lysine methyla-
tion sites are H3K4, H3K9, H3K27, H3K36, H3K79, and
H4K20 (Table 1), although many methylated-lysine resi-
dues have been found also in H1, H2A, H2B, and in fur-
ther positions within H3 and H4. While some lysine
methylation marks are preferentially associated with
euchromatin and hence gene activation (like H3K4,
H3K36, and H3K79) or with heterochromatin and
gene silencing (H3K9, H3K27, and H4K20) [24], more
often the final effect on chromatin is influenced by
the interplay of several histone modifications together
(“histone crosstalk”) [25].
Fig. 1 Nucleosome structure and principal modification sites on H3, H4, and DNA. The reported writers, erasers, and readers for these
modifications are also depicted
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Table 1 Principal writers and erasers of methyl lysines in histone 3 and 4 and their association with cancer
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An aberrant covalent histone modification profile,
leading to a dysregulated expression of oncogenes and
tumor suppressor genes, is often associated with cancer
[26]. Fraga et al. demonstrated, for example, that the re-
duction of Lys16 acetylation and Lys20 trimethylation at
histone 4 constitutes a typical “cancer signature” [27].
Furthermore, aberrant histone methylation has been re-
lated not only with cancer but also with mental retard-
ation and aging [28–30].
DNA methylation and histone acetylation were among
the first epigenetic targets to be addressed for drug devel-
opment and several inhibitors of DNA methyltransferases,
and histone deacetylases are approved by the Food and
Drug Administration (FDA) for clinical use in cancers
[31]. In contrast, histone methylation still offers a large
room for discovery and pharmacological interventions,
but lately, the first inhibitors have also reached clinical
testing. This review focuses on the recent reports on
clinical trials of compounds targeting reversible his-
tone lysine methylation and the biology behind their
targets. Some of this information is not yet published
in peer-reviewed journals, so statements on the clin-
ical activity of these inhibitors have to be viewed with
caution in these cases.
Review
Lysine methyltransferases
Up to date more than 50 lysine human methyltransfer-
ases (KMTs) have been reported. These enzymes possess
high selectivity concerning the histone lysine residue
they target, as well as the degree of methylation they can
confer. There are two different families of lysine methyl-
transferases divided on the basis of their catalytic do-
main sequence: the DOT1-like proteins and the SET
domain-containing proteins. The acronym SET came
from the Drosophila polycomb proteins in which this
domain was originally found, namely suppressor of
variegation 3–9 (Su(var)3–9), enhancer of zeste (E(z)),
and trithorax (Trx) [32–34]. These methyltransferases
methylate lysines in histones as well as in non-
histone substrates [35]. The KMT SET7/9, for ex-
ample, can stabilize the tumor suppressor p53 by
methylation at K372 [36]. It methylates also other
non-histone substrates, like the DNA methyltransfer-
ase 1 (DNMT1), estrogen receptor alpha (ERα), and
nuclear factor NFκB [37]. Among the KMTs, the hu-
man DOT1-like (DOT1L) protein is the only one
which does not possess a SET domain, and its cata-
lytic domain is structurally more similar to the argin-
ine methyltransferases [38, 39].
Based on the sequence similarity in their SET domain
and in adjacent protein regions, the SET demethylases
can be divided into four families: SET1, SET2, SUV39,
and RIZ [40, 41]. These methyltransferases generally
function in multiprotein complexes. The SET methyl-
transferase represents the catalytic domain, while the
accessory proteins control the selectivity and the activity
of the complex. The SET1 family is characterized by
the presence of the SET domain usually followed by a
post-SET domain, even if the two most studied mem-
bers of this family, EZH1 and EZH2, do not harbor
this region. The members of the SET2 class have a
SET domain that is always between a post-SET and
an AWS domain, rich in cysteines. In this family, we
find the nuclear receptor binding SET domain-
containing proteins NSD1-3, the SETD2 and the
SMYD family proteins. The SUV39 family members
all present a pre-SET domain, essential for enzymatic
activity [32]. SUV39H1, SUV39H2, G9a, GLP, ESET,
and CLLL8 belong to this class. Finally, the RIZ fam-
ily members, bearing the SET domain at the amino
terminus, are RIZ1, BLIMP1, and PFM1.
In addition to these families, there are other SET
domain-containing methyltransferases which have not
been assigned to a certain group, like SET7/9, SET8,
SUV4-20H1, and SUV4-20H2 [41]. Here, we highlight
those lysine methyltransferases for which the first inhibi-
tors are in clinical trials, more extended reviews can be
found elsewhere [26, 42, 43].
DOT1L
DOT1L protein is the mammalian homologue of dis-
ruptor of telomeric silencing-1 (Dot1), a gene found in
Saccharomyces cerevisiae [44]. DOT1L is the only en-
zyme responsible for mono-, di-, and trimethylation of
the ε-amino group on H3K79, an activating mark with
respect to gene transcription [33, 45]. The turnover of
this modification is generally slow and no KDM able to
remove this mark has been reported so far [46]. It has
been suggested that the monoubiquitinylation of
H2BK120 stimulates the H3K79 methyltransferase ac-
tivity of DOT1L [47, 48]. Min et al. were able to
solve the structure of the catalytic domain of human
DOT1L in complex with the methyl donor SAM at
2.5 Å, and a few years later, a 2.1 Å crystal structure
was reported [38, 49].
DOT1L plays a crucial role in various physiological
and pathological processes, like transcriptional regula-
tion, cell-cycle regulation, DNA repair, embryonic devel-
opment, hematopoiesis, cardiac function, and leukemia
development [39, 50–55]. Even if, to date, no genomic
alterations of DOT1L have been directly implicated in
cancer, this methyltransferase is a promising pharmaco-
logical target for the treatment of a unique group of leu-
kemias, which presents a chromosomal translocation of
the mixed-lineage leukemia (MLL) gene (chromosome
11q23). Examples are the acute myeloid leukemias
(AML), the acute lymphoblastic leukemias (ALL), and
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the biphenotypic (mixed lineage) leukemias (MLL).
These aggressive leukemia forms constitute more than
70 % of infant leukemias and about 10 % of adults’
leukemias and are associated with poor prognosis for
the patients: children affected by ALL harboring this
translocation have an overall survival of 50 %, whereas
children with ALL that does not harbor the MLL trans-
location have an overall survival of over 80 % [56–59].
The MLL gene normally encodes for a SET domain
KMT (MLL1) which performs the methylation of H3K4
[60]. When MLL is translocated, the catalytic methyl-
transferase SET domain is lost and the remaining MLL
protein is fused with a variety of partners known as
MLL translocation fusion proteins (like AF4, AF9, AF10,
and ENL) [61–63]. These fusion partners are able to re-
cruit DOT1L. Also, the nature of the fusion proteins can
influence the prognosis of the MLL-rearranged leuke-
mias; in particular, the association of MLL with AF10 is
associated with very poor outcomes [64]. These new
translocation product proteins retain, thus the gene
recognition elements of MLL, with the added ability to
recruit DOT1L. The resulting increased H3K79 methyla-
tion is a positive transcription mark that, bypassing the
normal transcription regulation, causes the expression of
proleukemogenic genes (like HOXA9 and MEIS1),
and thus the development of leukemia [65–67]. A
unique H3K79 methylation profile characterizes the
MLL-rearranged leukemias in comparison to the germ-
line MLL leukemias [61]. In several in vitro studies,
MLL-fusion-transformed cells, in which the expression
of DOT1L was suppressed or inactivated, showed differ-
entiation and apoptosis [68, 69]. These studies then sup-
port the hypothesis that the inhibition of DOT1L could
be a promising therapeutic strategy for the treatment of
MLL-rearranged leukemias.
Small molecules targeting DOT1L were designed using
the cofactor SAM or the enzymatic product S-adenosyl-
L-homocysteine (SAH) as the starting point (Fig. 2).
Generally, there are four classes of inhibitors: the SAH-
like, the mechanism-based, the carbamate-containing,
and the urea/benzimidazole-containing compounds. All
of them share a common adenosine or deazaadeno-
sine group, in analogy with the enzyme cofactor SAM
[70–77]. In 2011, Epizyme Inc. reported EPZ004777
as the first potent and selective inhibitor (Fig. 2) [72].
Crystal structures of this inhibitor and some analogs
within DOT1L were reported [73, 75]. EPZ004777
shows a remarkable selectivity against other histone
methyltransferases, which also use SAM as cofactor.
EPZ004777 was able to selective kill MLL-rearranged
leukemia cells in culture, while having little effect on
non-MLL translocated cells, and prolong survival in
mouse model of MLL-rearranged leukemia [72, 78].
However, despite these results, its poor pharmacokinetic
properties made this compound unsuitable for clinical de-
velopment. In a second generation of inhibitors, a novel
derivative of EPZ004777 was reported, in which the ribose
moiety was replaced with a cyclobutyl ring (EPZ-5676,
Fig. 2), to improve pharmacokinetic properties [77]. EPZ-
5676 shows the same binding mode as its parental
Fig. 2 a Schematic view of DOT1L principal domains. b Structures of the methyl donor SAM, its enzymatic product SAH and of two DOT1L
inhibitors. The SAM-like shared moiety is highlighted in bold
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compound, with an improved activity against DOT1L
(EPZ-5676 Ki <0.08 nM; EPZ004777 Ki = 0.3 nM), a
much-extended drug-target residence time and a 37,000-
fold selectivity against other protein methyltransferases
[77]. Both inhibitors showed a good activity against the
proliferation of some leukemia cell lines with MLL trans-
location, as MV4-11 (MLL-AF4), MOLM-13 (MLL-AF9),
and THP1 (MLL-AF9), with little effect on leukemia cells
lacking this translocation [71, 72, 77]. Despite the pharma-
cokinetic improvements, EPZ-5676 still showed a low oral
bioavailability [79]. Continuous infusion of EPZ-5676
(70 mg/kg per day) for 21 days achieved complete and
sustained tumor regressions (more than 30 days after the
end of treatment period) in a nude rat subcutaneous
xenograft model of MLL-rearranged leukemia. Interest-
ingly, these doses were also well tolerated with no overt
signs of toxicity in experimental animals. Reducing the
length of treatment to 14 days or the dose to 35 mg/kg
per day still caused sustained tumor regression, but with
less efficacy [77]. EPZ-5676 was also found to act synergis-
tically with cytarabine, daunorubicin, and the DNMT in-
hibitor azacitidine, three common AML standard care
drugs, in the human acute leukemia cell lines MOLM-13
(MLL-AF9) and MV4-11 (MLL-AF4) [80].
A first-in-human study of EPZ-5676 (now termed
Pinometostat) is currently in a phase I trial in adults
with AML and ALL with rearrangements of the MLL
gene (ClinicalTrials.gov identifier: NCT01684150). A
first part of the study with dose escalation, to determine
the maximum tolerated dose (MTD) and the recom-
mended phase 2 dose (RP2D), has been completed. Cur-
rently, this study is in the expansion phase, and patients
are receiving, in cycles of 28-day, continuous IV infusion
of EPZ-5676. The study has been completed in Novem-
ber of 2015. A phase I trial of EPZ-5676 recently opened
for pediatric patients with relapsed/refractory leukemias
bearing a rearrangement of the MLL gene (Clinical-
Trials.gov identifier: NCT02141828). The expected com-
pletion for primary outcome is May 2016.
EZH2
Enhancer of zeste homologue 2 (EZH2) belongs to the
SET1 family of methyltransferases. It is the catalytic
component of the polycomb repressive complex 2
(PRC2). Polycomb repressor complex 1 and 2 (PRC1
and PRC2, respectively) are transcriptional repressors
[81, 82]. They are involved in cellular memory, X-
chromosome inactivation, cancer metastasis, cell prolif-
eration, and cell differentiation via epigenetic histone
modifications [83, 84]. Gene silencing is achieved for
PRC1 via ubiquitylation of H2AK119, while PRC2 ex-
hibits histone lysine methyltransferase activity through
its catalytic subunit, represented by EZH2 or its close
homologue EZH1 [83, 85–87]. PRC2 performs three
successive methyl transfer reactions, producing ultim-
ately H3K27me3. EZH1 and EZH2 are the only enzymes
known to catalyze this epigenetic transformation. The
repressive effects of the polycomb complexes are coun-
teracted by the trithorax group proteins, a group of tran-
scriptional activators [88]. PRC2 consists of several
subunits, among them there are EZH2, embryonic ecto-
derm development (EED), and the suppressor of zeste
12 (SUZ12) [89]. Interestingly, EZH1/EZH2 lack enzym-
atic activity as isolated proteins, in fact, they are able to
methylate lysine residues only when they are in complex
with EED and SUZ12 [83, 90]. In addition to these three
subunits, PRC2 can bind other subunits, like AEBP2,
which regulates the activity or the localization of the
complex.
PRC2 seems to be required for the activity of PRC1 on
H2AK119. The exact mechanism is not completely
understood, but likely PRC2 performs H3K27 trimethy-
lation on target genes for the initiation of silencing.
Then PRC1 is recruited to these genes to consolidate the
silent state through ubiquitylation [91, 92]. PRC2 is also
able to interact, through the EED subunit, with other
histone modifiers, like histone deacetylases (HDAC) and
DNA methyltransferases (DNMT). Since H3K27 could
also bear an acetyl group, an initial HDAC activity is re-
quired before EZH2-mediated H3K27 methylation. The
PRC2 can then also associate with different DNMTs,
which perform cytosine methylation, then resulting in
gene silencing [93]. In summary, a model of poly-
comb gene silencing, initiated by PRC2, and main-
tained by PRC1, could be represented by histone
deacetylation, followed by histone methylation and
DNA methylation [91].
Several studies show that EZH2 deregulation is fre-
quently associated to poor prognosis in solid tumors, in-
cluding the prostate, breast, kidney, and lung [94–98].
EZH2 overexpression is also associated with metastasis,
tumor progression, and poor clinical outcome [99, 100].
Different mechanisms were reported as cause of in-
creased EZH2-dependent signaling in tumor cells, like
gene mutations [101], amplification [102], certain tran-
scriptional signals and pathways [103–105], hypoxia
[106], and multiple microRNAs [107–109]. Heterozy-
gous Tyr 641 mutations in the catalytic EZH2 SET do-
main, for example, were also identified in some myeloid
malignancies, especially in follicular lymphoma (7.2 %)
and in diffuse large B cell lymphoma (DLBCL) (21.7 %)
that derive from germinal center B cells [110]. Initially,
it was thought that this mutation caused loss of EZH2
methyltransferase activity, but later on was shown to
modulate the substrate specificity and to increase
H3K27me3 [111]. Regardless of the molecular mechan-
ism involved, EZH2 overexpression leads to higher levels
of the repressive H3K27me3 mark, responsible for the
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silencing of tumor suppressor genes in cancer cells. Sev-
eral inhibitors of EZH2 have been reported (Fig. 3). One
of the most studied compounds is 3-Deazaneplanocin A
(DZNep), a derivative of the antibiotic neplanocin-A
[112, 113]. DZNep is not a direct EZH2 inhibitor, but ra-
ther a SAH-hydrolase inhibitor. The increase of the
intracellular SAH concentration leads to the degradation
of the PRC2 complex by a feedback inhibition mechan-
ism [114]. DZNep was able to reactivate PRC2 target
genes, thus mediating apoptosis in cancer cells, like
brain, breast, colorectal, liver, lung, and prostate cancer
cells, but not in normal cells [112, 115]. Given the pleio-
tropic action of this inhibitor, its use as a chemical
probe, for specifically studying the EZH2 contribution in
the PRC2 overall activity, is very limited. Still, such a
multimodal inhibitor could be become a valuable drug
[116], but further rational optimization for second gen-
eration drugs is difficult in such a case. More recently,
research groups at GSK, Novartis, and Epizyme have
identified new hits for EZH2 inhibition from high-
throughput screening, and optimized them subsequently.
Many of them share a pyridone scaffold and the mech-
anism of action, namely competition with the cofactor
SAM. However, since there is not any EZH2-inhibitor
co-crystal structure (Wu et al. published a 2.0 Å crystal
structure of EZH2, without the cofactor or substrate)
[117], this mechanism of action is, for the moment, only
supported by the enzymology data. It is interesting to
notice that the effects of EZH2 inhibition are time
dependent. Given the slow kinetics of H3K27me3 turn-
over, it is not surprising that only a prolonged EZH2 in-
hibition (several days) is able to cause a H3K27me3
reduction, sufficient to alter the gene expression [118].
Of note is that the SAM competitive inhibitors are ef-
fective against cell lines bearing gain-of-function EZH2-
mutations (Tyr641 or Ala677), even if they induce a
decrease of H3K27me3 in both EZH2-mutated and wild-
type cancer cells [97]. We will focus particularly on the
inhibitors currently in clinical trials (Fig. 3). GSK343
demonstrated good activity against EZH2, in both en-
zymatic and cellular assays (EZH2 Ki app = 1.2 nM,
H3K27me3 cell IC50 = 174 nM in HCC1806 cells) [119].
It displays a very high selectivity, more than 1000-fold,
against other methyltransferases, and of 60-fold against
EZH1, which possesses a 96 % sequence identity of the
catalytic SET domain with EZH2. More recently, a new
inhibitor from GlaxoSmithKline was reported (GSK126),
which is the most potent EZH2 inhibitor (Ki app
0.3 nM, 150-fold selectivity against EZH1) reported so
far. GSK126 was able to effectively inhibit the prolifera-
tion of EZH2-mutant DLBCL cell lines and displayed a
robust activity in mice xenograft models of DLBCL
Fig. 3 a Schematic view of EZH2 principal domains. b Structures of EZH2 inhibitors
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bearing EZH2-activating mutations [120]. In April 2014,
GlaxoSmithKline began a phase1/2 dose escalation study
to investigate the safety, pharmacokinetics, pharmaco-
dynamics, and clinical activity of GSK2816126 (GSK126)
in patients with relapsed or refractory diffuse large B cell
and transformed follicular lymphoma (ClinicalTrials.gov
identifier: NCT02082977). This study will determine the
recommended phase 2 dose (RP2D) for GSK2816126
given i.v. Novartis reported EI1 (Fig. 3), an EZH2 inhibi-
tor which also binds to the SAM pocket of EZH2. It is
highly potent (EZH2 Ki = 13 nM) and selective (>10,000-
fold against other histone methyltransferases and about
90-fold against EZH1) [121]. In 2012, Epizyme reported
a potent EZH2 inhibitor (EPZ005687, Fig. 3) with a Ki of
24 nM, and >500-fold selectivity against other methyl-
transferases and 50-fold against EZH1. EPZ005687 se-
lectively inhibits H3K27 methylation of lymphoma cells
harboring heterozygous EZH2 mutations at Tyr641 or
Ala677, with minimal effects on proliferation on wild-
type cells [122]. One year later, the same group reported
EPZ-6438 (tazemetostat, formerly known also as E7438,
Fig. 3), with superior potency (EZH2 Ki = 2.5 nM) and
good oral bioavailability. EPZ-6438 demonstrated also
robust in vivo activity in a EZH2-mutant non-Hodgkin
lymphoma (NHL) mice xenograft model, causing dose-
dependent tumor growth inhibition. Two EZH2-mutant
xenograft models in mice dosed orally with EPZ-6438
for 28 days remained tumor free for up to 63 days after
stopping compound treatment [123, 124]. In June 2013,
a phase 1/2 clinical trial of tazemetostat has started in
patients with advanced solid tumors or with relapsed or
refractory B cell lymphomas (ClinicalTrials.gov identi-
fier: NCT01897571). The first part (dose escalation and
dose expansion phases) of this phase 1/2 trial is now
completed and EPZ-6438 showed a favorable safety and
tolerability profile, with the majority of adverse events of
grade 1 or grade 2, in particular asthenia, anorexia,
anemia, dyspnea, and nausea. Nine of 15 evaluable NHL
patients achieved an objective response, with two
complete responses and seven partial responses. One pa-
tient, evaluated for EZH2 status, possessed a specific
EZH2 tumor mutation (histidine instead of tyrosine 646,
Y646H). This patient achieved a partial response after
16 weeks of therapy and will remain on study. An 800-mg
dose twice per day is confirmed as the recommended
phase 2 dose. Pre-clinical data show a synergism between
tazemetostat and R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone) and between
tazemetostat and a not yet disclosed B cell signaling path-
way inhibitor in DLBCL (Epizyme, International Confer-
ence on Malignant Lymphoma (ICML), Recap
Presentation June 22, 2015). In November 2015, Epizyme
began a phase 1 study of tazemetostat in pediatric subjects
with relapsed or refractory integrase interactor 1 (INI1)
negative tumors or synovial sarcoma (ClinicalTrials.gov
identifier: NCT 02601937) and a phase II study for adult
patients with a similar cancer (ClinicalTrials.gov identifier:
NCT 02601950).
Treatment with EPZ-6438 caused also apoptosis in cell
lines and dose-dependent tumor regression in xenograft
model of malignant rhabdoid tumors with mutated
SMARCB1 (also known as SNF5, INI1, and BAF47), a sub-
unit of the SWItch/sucrose non-fermentable (SWI/SNF)
chromatin remodeling complex [124]. The SWI/SNF com-
plex consists of approximately 15 subunits and contributes
to transcriptional regulation and DNA repair. It has been
shown that at least nine of its subunits are frequently mu-
tated in a wide variety of cancers (20 % of all human tu-
mors) [125]. In addition to SMARCB1, other SWI/SNF
subunits are often mutated in cancer like ARID1A in ovar-
ian carcinoma [126], SMARCA4 (also known as BRG1) in
lung and pancreas cancer [127, 128], and PBRM1 in renal
cancer [129]. It has been demonstrated that the inactiva-
tion of these subunits renders the cancer cells functionally
dependent on the EZH2 catalytic activity, and the treat-
ment with EZH2 inhibitors gave very promising results
against tumors harboring SWI/SNF mutations [124, 126].
However, very recently, Kim and co-workers demonstrated
that the SWI/SNF mutant cancer cells are only partially
dependent on the EZH2 histone methyltransferase activity;
they suggest that the dependence on EZH2 could arise
from a non-enzymatic contribution of EZH2, like its role
in the stabilization of the PRC2 complex [130].
Finally, also Constellation Pharmaceuticals reported a
series of benzamide inhibitors that are SAM-competitive.
The most active compound of the series inhibited EZH2
with an IC50 of 32 nM [131]. In March 2015, they have
begun a phase I clinical trial of CPI-1205, a novel inhibitor
of EZH2, in patients with B cell lymphomas (ClinicalTrials.-
gov identifier: NCT02395601). The chemical structure of
this inhibitor as not yet been disclosed, it is expected to be-
long to the pyridone family, similar to the inhibitor CPI-
169 (Fig. 3), published by the same research group [118].
Lysine demethylases
Up to date, two classes of KDM have been described:
the amine-oxidase type lysine-specific demethylases 1
and 2 (LSD1 and 2; also known as KDM1A and B, re-
spectively) and the JumonjiC (JMJC) domain-containing
histone demethylases. The latter consist of a group
which contains over 30 members and can be divided,
based on the JMJC-domain homology, into seven sub-
families (KDM2-8) [21, 132, 133]. These two classes of
demethylases possess different catalytic mechanism. The
LSD-family members are flavin adenine dinucleotide
(FAD)-dependent amine oxidases that generate an imine
intermediate that is hydrolysed to the demethylated ly-
sine and formaldehyde. Upon recycling of the cofactor
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FAD, hydrogen peroxide is formed as a byproduct of de-
methylation. As these enzymes require a free electron
pair on the lysine ε-nitrogen atom to initiate demethyla-
tion, LSD1 and 2 are able to demethylate only mono-
and dimethylated but not trimethylated lysines [21]. The
Jumonjii domain-containing demethylases are iron and α-
ketoglutarate (2-oxoglutarate (2-OG))-dependent en-
zymes. They are able to remove methyl groups from all
three methyl lysine states, with concomitant production of
succinate, carbon dioxide, and the demethylated lysine
and formaldehyde [134, 135]. The target specificity of
KDMs is regulated by their participation in different com-
plexes. KDMs are implicated in different diseases, such as
leukemia, prostate and breast cancer, esophageal squa-
mous carcinoma, and as mental retardation [26, 136, 137].
LSD1/KDM1A
LSD1 bears an amine oxidase-like domain (AOL) at the C-
terminal end which displays two folded subdomains: the
FAD- and the substrate-binding region. While the FAD-
binding subdomain shares many similarities with other
FAD-dependent amine oxidases, the substrate-binding sub-
domain is much larger than in other amine oxidases and is
able to accommodate several residues near the target lysine
[138]. At the N-terminal, the SWIRM domain is important
for the protein stability and for the interactions with
histone-tails. A tower domain is located within the catalytic
center, and it seems to be important for the interaction with
other proteins to form complexes, like the co-repressor of
RE1-silencing transcription factor (CoREST), HDAC1/2, or
the C-terminal-binding protein 1 (CtBP1) [135, 138, 139].
The substrate specificity of LSD1 is influenced by its associ-
ation with different partners. For example, LSD1 generally
demethylates H3K4me1/2, thus repressing gene transcrip-
tion, but when LSD1 interacts with the androgen recep-
tor (AR), its enzymatic specificity switches to H3K9me1/2,
then stimulating transcription [140]. In addition to
H3K4me1/2 and H3K9me1/2, LSD1 is also able to demeth-
ylate lysines in non-histone proteins like K370 in the tran-
scription factor p53, K185 of E2F1, and K1096 in DNMT1
[141–143]. LSD1 itself in turn is also a substrate for methy-
lation. Dimethylation of LSD1 at lysine (K) 114 by the his-
tone methyltransferase G9A results in the recruitment of
the chromatin remodeler chromodomain-helicase-DNA-
binding protein 1 (CHD1), which is a key event controlling
androgen-dependent target gene transcription and signaling
dependent on the TMPRSS2-ERG fusion [144]. Import-
antly, preventing LSD1 methylation or interaction of CHD1
with methylated LSD1 severely impaired chromatin recruit-
ment of CHD1 and AR, androgen-dependent target gene
transcription, chromatin loop formation at the TMPRSS2
locus, and TMPRSS2-ERG gene fusion. This makes target-
ing of this methylation namely the interaction a promising
target for the treatment of prostate cancer.
As the LSD enzymes are structurally related to the
monoaminoxidases MAO-A and MAO-B, some MAO
inhibitors, as tranylcypromine (TCP; Fig. 4), an approved
drug for the treatment of depression, were among the
Fig. 4 a Schematic view of LSD1 principal domains. b Structures of the unselective LSD1/MAO inhibitor tranylcypromine (TCP), the selective LSD1
inhibitors from Oryzon and GSK and the dual HDAC/LSD1 inhibitor 4SC-202
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first discovered KDM1 inhibitors. The TCP is a
mechanism-based irreversible inhibitor which bonds to
the cofactor FAD [145]. However, the use of unselective
compounds as KDM1 inhibitors is limited by their anti-
MAO activities. The most common side effects caused
by MAOIs include orthostatic hypotension, dizziness,
and drowsiness [146, 147]. Moreover, in 1963, Blackwell
reported the possibility of hypertensive crises associated
with assumption of MAOIs and tyramine-containing
foods (like cheeses) [148]. Thus, patients in dose-
escalation trials with TCP must be instructed to avoid
critical food and have to be monitored intensively to
prevent undesired cardiovascular events. TCP was re-
cently reported to inhibit the colony-forming ability of
AML cells in a mouse model of MLL-AF9-induced
leukemia [149]. It is to note that, in this study, a drug-
induced anemia in mice was also reported. Many TCP
derivatives have been prepared in order to get more se-
lective LSD1, MAO-inactive compounds [150, 151].
Those would not have the CNS effects of unselective in-
hibitors and not pose the risk of dangerous interactions
with tyramine from food.
Acute promyelocytic leukemia (APL) is a very curable
subtype of AML, since APL cells are highly sensitive to
all-trans retinoic acid (ATRA). Over 80 % of APL patients
can be treated successfully with ATRA-based therapies.
For patients with non-APL AML, ATRA has little effect.
Consequently, 85 % of these patients will succumb to their
disease despite conventional approaches. Little is known
about mechanisms of resistance to ATRA in non-APL
AML, but data strongly suggest that LSD1 may contribute
to ATRA resistance. TCP, as an LSD1 inhibitor, can re-
sensitize non-APL AML cells to ATRA [152]. A phase I/II
trial of Tretinoin (ATRA, the carboxylic acid form of
vitamin A) and TCP was started in September 2014 by a
research group of the Martin-Luther-University of Halle-
Wittenberg, Germany, in patients with AML who cannot
tolerate an intensive chemotherapy (ClinicalTrials.gov
identifier: NCT02261779 and EudraCT Number: 2012-
002154-23). In October 2014, the University of Miami
started a phase 1 study on the safety and tolerability of
TCP/ATRA combination therapy in patients with AML
and myelodysplastic syndromes (MDS) (ClinicalTrials.gov
identifier: NCT02273102). In the trial, increasing doses of
TCP (10, 20, 40, and 60 mg) are administrated orally twice
a day together with 45 mg/sqm of Tretinoin. In the study
of Halle University, patients are treated with daily increas-
ing doses of TCP (initially 10 mg/day, then +10 mg each
day up to 80 mg/day) and after 7 days, ATRA is added at
a fixed dose (45 mg/sqm/day). The combination of TCP,
ATRA, and the chemotherapy agent cytarabine is in a
phase I/II study by the University of Freiburg for the treat-
ment of patients with AML and MDS (German Clinical
Trials Register, DRKS-ID: DRKS00006055). In the trial,
four dose levels of TCP (20, 40, 60, and 80 mg on days 1–
28) are examined in combination with fixed dose of ATRA
(45 mg/m2 on days 10–28) and fixed dose of cytarabine
(40 mg on days 1–10) for the first cycle, for the following
cycles, ATRA is administered continuously, except for a
9-day interruption at the beginning of every fourth cycle.
Many TCP derivatives have been reported, some of
them, with potency in the low nanomolar range and a
very high selectivity over MAOs, were able to induce dif-
ferentiation in a mouse model of human MLL-AF9
leukemia [149]. Oryzon reported ORY-1001 (Fig. 4), a
potent and selective LSD1 inhibitor (IC50 of 18 nM and
selectivity over MAOs and LSD2 over 1000-fold), which
is able to show a time- and dose-dependent H3K4me2
accumulation at KDM1A target genes and induction of
differentiation markers in THP-1 cells with MLL trans-
location (MLL-AF9). It also possesses good oral bioavail-
ability, and daily oral administration of doses lower than
0.020 mg/kg leads to significantly reduced tumor growth
in rodent MV(4;11) xenografts [153, 154]. ORY-1001 is
currently in a phase I/IIA clinical trial in patients with
relapsed or refractory acute leukemia (EudraCT Num-
ber: 2013-002447-29). In April 2014, Roche and Oryzon
Genomics started a collaboration on LSD1-inhibitors re-
search and Roche will have sole responsibility for devel-
oping and commercializing ORY-1001. GlaxoSmithKline
reported also a selective LSD1 inhibitor, GSK2879552
(Fig. 4), which entered a phase I study in AML (Clin-
icalTrials.gov identifier: NCT02177812) and in small
cell lung cancer (SCLC) (ClinicalTrials.gov identifier:
NCT02034123). GSK2879552 promotes differentiation
in AML cells and treatment with this inhibitor re-
sulted in a potent anti-proliferative growth effect in
SCLC cells and AML cells. Furthermore, mouse models of
AML and SCLC treated with GSK2879552 showed pro-
longed survival [155]. GlaxoSmithKline has also disclosed
a reversible KDM1A inhibitor (GSK354 or GSK690) with
both high potency (IC50 <100 nM), highly selectivity
(MAO IC50 >200 μM) and good cellular activity [156].
Additional pre-clinical studies are warranted to validate
this compound as a therapeutically promising KDM1A
inhibitor.
Interesting is also the use of dual HDAC-LSD1 inhibi-
tors. An example is 4SC-202 (Fig. 4), which inhibits
HDAC1/2/3 and LSD1 with similar low micromolar
potency. 4SC-202 provokes the inhibition of stemness-
related properties of cancer cells and affects their viabil-
ity [157]. It has, in March 2015, ended a phase I trial in
patients with advanced hematological malignancies, and
it showed to be well tolerated and to possess anti-cancer
activity (ClinicalTrials.gov identifier: NCT01344707)
[158]. Very interesting is also the reported synergistic le-
thal effect against cultured and primary AML blasts
showed by the combination of SP2509, a very potent
Morera et al. Clinical Epigenetics  (2016) 8:57 Page 10 of 16
LSD1 inhibitor with panobinostat, a pan-HDAC inhibi-
tor. Compared with each agent alone, co-treatment
significantly improved the survival of the mice engrafted
with the human AML cells, without exhibiting any
toxicity [159].
In December 2015, the Californian company, Imago
Biosciences, has announced, for the next year, the begin-
ning of a clinical trial for an oral Imago LSD1 inhibitor
for the treatment of myelofibrosis (www.imagobio.com).
JMJC demethylases
While for LSD1, already four compounds are in clinical
trials, the development of clinical candidates against the
JMJC domain-containing demethylases is not as ad-
vanced. The development of potent and selective JMJC
domain-containing demethylases inhibitors is much
more complicated. The big challenges come from the
high structural similarity of its members and also from
the generally poor cellular permeability of the inhibi-
tors since now disclosed (many of which are metal
chelators, 2-OG analogs). The KDM5 subfamily, also
known as JARID1, demethylates H3K4me2/3; the ac-
tivities of these enzymes are related with cancer pro-
liferation, reduction of tumor suppressor expression,
and drug resistance and relapse [160].
The Danish company, EpiTherapeutics, reported EPT-
103182, a small molecule, targeting KDM5B with subna-
nomolar potency in vitro and a cellular IC50 of 1.8 nM in
U2OS cells, with 20–50-fold selectivity against KDM4 and
3000-fold against KDM6 [153]. EPT-103182, which struc-
ture has not yet been disclosed, is the most advanced
KDM inhibitor in preclinical development, it shows an an-
tiproliferative effect in hematological and solid cancer cell
lines, and demonstrates dose-dependent tumor growth in-
hibition in xenograft models [161]. In May 2015, Gilead
Sciences has acquired EpiTherapeutics.
Quanticel Pharmaceuticals patented a series of pyridine
derivatives as JARID1A (KDM5A), JARID1B (KDM5B),
JMJD2C (KDM4C), and FXBL10 (KDM2B) inhibitors
(WO 2014100463 A1 and WO 2014151945 A1). The
company was recently acquired by Celgene Corporation
and first drug candidates from Quanticel are expected to
enter the clinic trials in early 2016 (www.quanticel.com).
Conclusions
Epigenetics provides promising new targets for antican-
cer therapy. DNA methylation and histone acetylation
were already addressed for drug design and several DNA
methyltransferases and histone deacetylases inhibitors
are FDA-approved anti-cancer drugs. More recently,
compounds targeting histone methylation have entered
in clinical trials for cancer treatment. In this review, we
summarized the last reports in clinical trials for DOT1L,
EZH2, and LSD1 inhibitors. EPZ-5676 (pinometostat), a
DOT1L inhibitor, is currently in phase I trial in patients
with AML with MLL translocation. Even if EPZ-5676 has
a low oral bioavailability and the treatment needs to use
high drug concentrations, this inhibitor showed promising
results in patients afflicted by MLL-rearranged leukemia.
EZH2 inhibitors seem to be particularly effective against B
cell lymphomas bearing EZH2-activating mutations.
GSK126 from GlaxoSmithKline, tazemetostat from Epi-
zyme, and CPI-1205 from Constellation Pharmaceutical
are currently in phase I clinical trials for the treatment of
this form of NHL. The LSD1 inhibitor TCP could re-
sensitize AML cells to ATRA and the Universities of
Halle, Miami, and Freiburg are testing the TCP/ATRA
combination in patients with AML. Regarding other LSD1
inhibitors, ORY-1001 from Oryzon is in phase I/IIA trial
for the treatment of acute leukemia, GSK2879552 is under
a phase I clinical trial in patients with AML and SCLC,
and 4SC-202, a HDAC1-3 and LSD1 inhibitor ended a
phase I trial for hematological malignancies.
This field has just begun to be addressed and, for the
moment, the number and the chemical diversity of KMT
inhibitors available are limited and, more important, for
some KMTs, which could be important targets in cancer
therapies (like WHSC1 and KMT2), there are no inhibi-
tors reported yet. Regarding the KDMs, due to the high
similar structures of the Jumonji demethylases and the
analogy of KDM1 with MAOs, the major challenge is the
identification of subtype-selective inhibitors.
Because cross talk can occur between histone methyla-
tion and acetylation, a combination of epi-inhibitors
targeting these two modifications could represent an in-
teresting approach for future therapeutic intervention.
In the last decade, combinations of drugs that modify
chromatin or DNA methylation status have already been
shown to produce a synergistic reactivation of tumor-
suppressor genes and an enhanced anti-cancer effect in
several malignancies, like colon [162], cervical [163], and
endometrial cancer [164]. Combination therapies are ex-
pected to improve the efficacy of the single drugs, in
part by limiting acquired resistances and by reducing the
side effects through the use of lower dosages of one or
both drugs [165]. A combination of the HDAC inhibitor
Vorinostat with the LSD1 inhibitor pargyline has re-
cently shown a promising antineoplastic efficacy results
in human breast cancer cells [166, 167].
Moreover, the modulation of an aberrant histone methy-
lome profiles could be addressed also through an action
on the readers of this modification. This strategy was suc-
cessful for histone acetylation; in fact, inhibitors of bromo-
domains, proteins that bind and recognize histone
acetylation, are in advanced pre-clinical and clinical stud-
ies for the treatment of hematological malignancies [168].
At present, few inhibitors of the histone methylation
readers have been reported, but for many targets, no
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small-molecule ligands are known yet [169]. Recently,
we reported the first nanomolar inhibitor of a Tudor
domain-containing methyl-lysine reader protein, Spin-
dlin1, which has been reported to be involved in lipo-
sarcoma proliferation [170, 171].
Initial results of current clinical trials with drugs tar-
geting the histone methylome will probably guide the fu-
ture clinical development for new histone methylation
modifiers and different therapeutic indications. Still,
there is a plethora of targets around histone methylation
and demethylation that has not been properly addressed
by inhibitors so far, and thus, there will be many further
opportunities for epigenetic therapy.
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